NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Whitepaper: The Power of Partnership in Advancing Innovation
Sutro Biopharma and Boehringer Ingelheim collaborate to scale-up a novel cell-free technology platform to produce ADCs. Explore how cell-free ADC manufacturing is shaping cancer therapy.
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
SOUTH SAN FRANCISCO, Calif., September 29, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organizational restructuring to prioritize...
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research collaboration with the FDA to...
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
SOUTH SAN FRANCISCO, Calif., July 22, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the...
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 2, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial...
21st Annual PEGS Boston Summit – Presentation
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS,...
The Citizens Life Sciences Conference – Presentation
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 1, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming...
2025 American Association for Cancer Research (AACR) Annual Meeting – Poster Presentations
Title: Preclinical activity and safety of STRO-004, a novel ADC targeting tissue factor for solid tumors Abstract: #1572 Session: PO.ET02.01 - Antibody-Based Cancer Therapeutics 1 Date & Time: Monday, April 28, 2025, 9:00 a.m. - 12:00 p.m. CTPresenter: Alice Yam,...